![](https://static.wixstatic.com/media/cd6738_84569b87907749eb8ee0cbfd6670657d~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_84569b87907749eb8ee0cbfd6670657d~mv2.webp)
![NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)](https://static.wixstatic.com/media/cd6738_84569b87907749eb8ee0cbfd6670657d~mv2.jpeg/v1/fill/w_269,h_182,fp_0.50_0.50,q_90,enc_auto/cd6738_84569b87907749eb8ee0cbfd6670657d~mv2.webp)
Dec 6, 2018
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
Multiple Myeloma Research Consortium MyDRUG RRMM NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG) Multiple...
358
![](https://static.wixstatic.com/media/cd6738_70fcd54d159f4bd3acfdb7cefa732e30~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_70fcd54d159f4bd3acfdb7cefa732e30~mv2.webp)
![NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs](https://static.wixstatic.com/media/cd6738_70fcd54d159f4bd3acfdb7cefa732e30~mv2.jpg/v1/fill/w_269,h_181,fp_0.50_0.50,q_90,enc_auto/cd6738_70fcd54d159f4bd3acfdb7cefa732e30~mv2.webp)
Dec 8, 2016
NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs
NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a...
90